#INSACOG

[kennak]

新型コロナウイルス感染症のサイクルが再び回転し、新たな変異種が流通しています。 「FLiRT」亜種と呼ばれるKP.2とKP1.1は、昨年の冬に世界的に蔓延したOmicron JN.1の子孫です。 アメリカ感染症協会（IDSA）によると、下流の変異種は米国での新規感染者と入院者数のわずかな増加に関連しているという。 FLiRTの感染者数は英国、韓国、ニュージーランドでも急増しており、新型 コロナウイルス感染症の新たな波に対する懸念が改めて高まっている。 インド SARS-CoV-2 ゲノミクス コンソーシアム (INSACOG) は、5 月 6 日の時点で、インドで流行している KP.2 症例 238 例と KP1.1 症例 30 例を検出しました。

FLiRT、新しい新型コロナウイルスの亜種について | 解説 - ヒンドゥー教

[industrynewsupdates]

Genomics Market Business Growth, Opportunities and Forecast 2024-2030

The global genomics market size was valued at USD 32.65 billion in 2023 and is projected to witness a compound annual growth rate (CAGR) of 16.5% from 2024 to 2030. 

The growth of genomics market is attributed to factors such as growing demand for gene therapy, personalized medicine, drug discovery, increasing cancer incidence, and a significant increase in demand for consumer genomics in recent years. Moreover, increasing number of joint ventures and partnerships amongst market players is also expected to have a positive impact on the genomics market growth. For instance, in June 2022, Illumina, Inc., and Allegheny Health Network signed a collaboration for effective evaluation of the impact of in-house Comprehensive Genomic Profiling (CGP) to leverage patient care.

Gather more insights about the market drivers, restrains and growth of the Genomics Market 

The COVID-19 pandemic outbreak had posed challenges to applications of genomics technology in terms of research and therapeutics. Nevertheless, some niche applications were of great use to mankind during the pandemic situation to facilitate immediate attention for designing effective diagnostics, effective therapeutics and steps to curb the spread of COVID-19.  For example, the viral genome mutational rate (~1-2 bases per month) was gauged for validity of PCR cycle was estimated to understand the efficacy of the re-purposed anti-viral treatments and thereby the vaccine development process was streamlined.

Many genomic surveillance programs were launched country wise to understand the dynamics of pandemic situation and to effective preventive measures. For instance, in December 2020, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) was launched by the joint efforts of Department of Biotechnology (DBT), Ministry of Health, and ICMR with an aim to screen the genomic variations in the SARS-CoV-2 by sequencing technologies. Furthermore, country specific companies are providing consumer genomics services which is also expected to fuel the market size in coming years. One such company being Mapmygenome which is one of the pioneers in India offers DTC genomics services.

The increasing prevalence of inherited cancers is expected create a high demand for cancer genomics. The substantial understanding of human genome have targeted focus on use of various gene therapies for treatment of cancers by modern gene editing techniques such as CRISPR-Cas gene technology. For instance, in September 2022, a group of researchers at the University of California introduced the applications of precision genome editing agents for management of inherited retinal diseases (IRDs).

The development of high-throughput sequencing technologies such as Next-Generation Sequencing (NGS) and microarrays has generated massive amounts of genomic data. However, the rapid accumulation of this data from DNA sequencing and Electronic Health Records (EHRs) poses significant challenges and opportunities for the extraction of biologically or clinically relevant information. Phenome-wide association study (PheWAS) & genome-wide association study (GWAS) are helping researchers to study correlations between genotype and phenotype.

The market players are extensively working towards collaborations, expansions, acquisitions and huge capital investments to advance in research to understand rare diseases and to aid drug discovery. For instance, PacBio declares a collaboration with the Genomics England society for the utility of PacBio’s technology to detect genetic variation in unexplained rare disorders. The study is intended to re-sequence a selection of samples collected during Genomics England’s 100,000 genomes project to discover potential operational and clinical benefits of long-read sequencing for the identification of mutations associated with rare diseases.

Genomics Market Segmentation

Grand View Research has segmented the global genomics market based on application, technology, deliverables, end-use, and region:

Application & Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Functional Genomics

• Transfection

• Real-Time PCR

• RNA Interference

• Mutational Analysis

• SNP Analysis

• Microarray Analysis

• Epigenomics

• Bisulfite Sequencing

• Chromatin Immunoprecipitation (ChIP & ChIP-Seq)

• Methylated DNA Immunoprecipitation (MeDIP)

• High-Resolution Melt (HRM)

• Chromatin Accessibility Assays

• Microarray Analysis

• Pathway Analysis

• Bead-Based Analysis

• Microarray Analysis

• Real-time PCR

• Proteomics Tools (2-D PAGE; yeast 2-hybrid studies)

• Biomarker Discovery

• Mass Spectrometry

• Real-time PCR

• Microarray Analysis

• Statistical Analysis

• Bioinformatics

• DNA Sequencing

• Others

Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Sequencing

• PCR

• Flow Cytometry

• Microarrays

• Other technologies

Deliverables Outlook (Revenue, USD Billion, 2018 - 2030)

• Products

o Instruments/Systems/Software

o Consumables & Reagents

• Services

o NGS-based Services

o Core Genomics Services

o Biomarker Translation Services

o Computational Services

o Others

End-use Outlook (Revenue, USD Billion, 2018 - 2030)

• Clinical Research

• Academic & Government Institutes

• Hospitals & Clinics

• Pharmaceutical & Biotechnology Companies

• Other End Users

Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o India

o Japan

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global cell sorting market size was valued at USD 242.7 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2030. 

• The global live cell imaging market size was valued at USD 2.48 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030.

Key Companies & Market Share Insights

The market players operating in the genomics market are adopting product approval to increase the reach of their products in the market and improve the availability of their products & services in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Key Genomics Companies:

• Agilent Technologies

• Bio-Rad Laboratories, Inc.

• BGI Genomics

• Color Genomics, Inc.

• Danaher Corporation

• Eppendorf AG

• Eurofins Scientific

• F. Hoffmann-La Roche Ltd.

• GE Healthcare

• Illumina, Inc.

• Myriad Genetics, Inc.

• Oxford Nanopore Technologies

• Pacific Biosciences of California, Inc.

• QIAGEN N.V.

• Quest Diagnostics Incorporated

• Thermo Fisher Scientific, Inc.

• 23andMe, Inc.

Recent Development

• In November 2023, Fabric Genomics collaborated with DNAnexus and Oxford Nanopore Technologies for deployment of CLIA/CAP labs in pediatric and neonatal ICU’s. The labs will use Oxford Nanopore’s platforms to study genetic disorders in infants.

• In February 2023, Illumina, Inc. entered into a collaboration with African Centre of Excellence for Genomics of Infectious Diseases to start a training institute to increase genomic capabilities in African region

• In January 2023, SOPHiA GENETIC collaborated with the Memorial Sloan Kettering Cancer Center (MSK), a U.S. Cancer Center, to offer researchers and clinicians solutions to expand analytical and testing capabilities.

• In January 2023, Agilent Technologies, Inc. announced acquisition of Avida Biomed, a company that develops target enrichment workflows for clinical researchers utilizing NGS methods to study cancers.

• In April 2022, QIAGEN launched the Biomedical Knowledge Base in Europe, Japan, North America, and Australia to support data science applications in biotech companies 

Order a free sample PDF of the Genomics Market Intelligence Study, published by Grand View Research.

[deepkingstudent]

Covid-19 JN.1 news Highlights: INSACOG says 157 cases recorded in India, highest from Kerala | Mint - Mint

http://dlvr.it/T0j937

[morningmantra]

JN.1 Covid Variant: 'No need for extra dose vaccine'…Dr. NK Arora

Dr. NK Arora, Chief of 'Insacag', said that no additional dose of vaccine is required for the new subtype of Covid JN.1.

Dr. NK Arora, Chief of ‘Insacag’, said that no additional dose of vaccine is required for the new subtype of Covid JN.1. Delhi: A new subtype of Covid (Covid-19) that has come to light in the country is JN. 1 (JN.1) does not require an additional dose of vaccine, said Dr NK Arora, Chief of Sars-Cov-2 Genomics Consortium (INSACOG). However, people are advised to be vigilant to prevent the spread…

[starfriday]

Dr. Mansukh Mandaviya reviews COVID-19 Situation and Preparedness of public health system for Surveillance, Containment and Management in view of rising COVID-19 Cases in some parts of the country

It is important to be on alert and be prepared against new and emerging strains of COVID-19 virus: Dr Mandaviya

Reiterates the need for joint efforts between Centre and States to ensure efficient management of COVID-19

“Let us undertake mock drills once every three months at both Central and State levels and share best practices”

States to monitor emerging evidences of COVID-19 cases, symptoms and case severity to plan appropriate public health response

States/UTs advised to send samples of all Covid-19 positive cases to INSACOG labs to facilitate tracking of new variants

States urged to create awareness, manage infodemic and ensure dissemination of factually correct information

Posted On: 20 DEC 2023 1:01PM by PIB Delhi

Dr. Mansukh Mandaviya, Union Minister of Health and Family Welfare today chaired a high-level meeting to review the COVID-19 situation in India and preparedness of public health system for surveillance, containment and management of COVID-19 in view of the recent spike in cases of COVID-19 in some states. He was joined by Prof. S P Singh Baghel and Dr Bharati Pravin Pawar, Union Ministers of State for Health and Family Welfare. Dr V K Paul, Member (Health), NITI Aayog was also present.

State Ministers who joined the meeting include Shri Alo Libang, Chief Minister and Minister of Health (Aruachal Pradesh); Shri Brajesh Pathak, Deputy Chief Minister and Health Minister (Uttar Pradesh); Shri Dhan Singh Rawat, Health Minister (Uttarakhand) who was present physically; Shri Dinesh Gundu Rao, Health Minister (Karnataka); Shri Anil Vij, Health Minister (Haryana); Smt. Veena George, Health Minister (Kerala), Shri Vishwajit Pratapsingh Rane, Health Minister (Goa); Shri Keshab Mahanta, Health Minister (Assam), Shri Banna Gupta, Health Minister (Jharkhand); Dr Balbir Singh, Health Minister (Punjab); Shri Saurabh Bharadwaj, Health Minister (Delhi); Dr. (Col.) Dhani Ram Shandil, Health Minister (Himachal Pradesh); Prof. Dr. Tanajirao Sawant, Health Minister (Maharashtra); Shri Damodar Rajanarasimha, Health Minister (Telangana); Dr Sapam Ranjan, Health Minister (Manipur); Shri Niranjan Pujari, Health Minister (Odisha); Shri Rangaswamy, Administrator (Puducherry); among others.

Underlining the challenge posed by the increasing number of COVID-19 cases in some countries across the world such as China, Brazil, Germany and United States, Union Health Minister noted the importance of being prepared and remaining alert against new and emerging strains of COVID-19, especially in view of the upcoming festive season. Underlying and reiterating that COVID is not over yet, he requested states to monitor emerging evidences of COVID-19 cases, symptoms and case severity to plan appropriate public health response.

Dr Mandaviya stressed the need for collective efforts between the Centre and the States to deal with the emerging situation in the spirit of “Whole of Government” approach. He directed for strengthening the surveillance system for whole genome sequencing of positive case samples to track the variants through Indian SARS-CoV-2 Genomics Consortium (INSACOG) network to ensure timely detection of newer variants, circulating in the country. This would facilitate undertaking of appropriate public health measures in a timely manner, he noted. States/UTs have been requested to ramp up testing and refer large number of samples of COVID-19 positive cases and pneumonia-like illness to INSACOG Genome Sequencing Laboratories (IGSLs) on a daily basis, for sequencing, to track new variants, if any.

The Union Health Minister urged all the states to remain alert, increase surveillance and ensure adequate stock of medicines, oxygen cylinders and concentrators, ventilators and vaccines, He asked officials to undertake mock drills every three months at both the Central and State levels to assess functionality of PSA plants, Oxygen concentrators and cylinders, ventilators, etc., and encouraged the sharing of best practices. He also urged states to create awareness on respiratory hygiene and ensure dissemination of factually correct information and counter fake news to manage infodemic and mitigate any panic. The Union Health Minister urged States/UTs to share information on cases, tests, positivity etc., in real time on the COVID portal to enable timely monitoring and prompt public health measures. He assured the states of all support from the Centre.

Through a presentation, Shri Sudhansh Pant, Secretary, Union Health Ministry briefed the Union Health Minister on the global COVID19 situation and the domestic scenario. It was informed that while active COVID cases in India are significantly less compared to the global scenario, in the last two weeks there has been a steep rise in active cases from 115 on 6th Dec 2023 to 614 on date. It was also noted that 92.8% of the cases are home isolated, indicating mild illness. No increase in hospitalization rates have been witnessed due to COVID-19, the cases that are hospitalized are due to other medical conditions – COVID-19 is an incidental finding. A rise in daily positivity rate has been observed in a few states like Kerala, Maharashtra, Jharkhand and Karnataka.

On the new JN.1 variant of SARS-CoV-2, it was informed that the variant is currently under intense scientific scrutiny, but not a cause of immediate concern. No clustering of cases has been observed in India due to JN.1 and all the cases were found to be mild and all of them have recovered without any complications.

Dr V K Paul reiterated the need for a whole-of-government approach to tackle with the challenge posed by the surge in COVID cases and the emergence of a new variant. He informed that the scientific community in India is closely investigating the new variant but stressed on the need for states to ramp up testing and strengthen their surveillance systems.

Dr Rajiv Bahl, Secretary, Department of Health Research and DG, ICMR informed that ICMR is currently working on genome sequencing of the new JN.1 variant. He urged states to monitor the COVID-19 scenario and increase RT-PCR tests but noted that there is no cause for panic.

State Health Ministers appreciated the support and guidance received from the Centre. They assured to increase testing and surveillance measures in view of the rising cases in some states.

Smt. L S Changsan, Addl. Secretary, Union Health Ministry; senior officials from the Health Ministry, ICMR, and NCDC were present in the meeting.

****

MV

HFW/ HFM COVID Review Meeting/20December2023/1

[typoeastnews]

India Issues Urgent Advisory Amidst Surging Covid Cases

In response to the alarming spike in Covid-19 cases across India, the Centre issued a crucial advisory on Monday, urging all states to step up their efforts in combating the pandemic. According to data from the Union Health Ministry, India reported 260 new coronavirus infections in the last 24 hours.

In a letter addressed to the Health Secretaries of all states and Union Territories, the government emphasized the need for constant vigilance and prompt action to curb the spread of the virus. States were directed to closely monitor and report district-wise Severe Acute Respiratory Illness (SARI) and Influenza-like Illness (ILI) cases on a regular basis.

The advisory highlighted several key measures that states should implement immediately:

Public Health Measures: States were advised to implement necessary public health measures and arrangements to minimize the risk of Covid-19 transmission.

Compliance with Operational Guidelines: States were urged to ensure effective compliance with detailed operational guidelines for the revised surveillance strategy, as provided by the Union Ministry of Health and Family Welfare.

Testing and Reporting: The Centre stressed the importance of adequate testing, including a higher number of RT-PCR tests. States were instructed to report and monitor district-wise ILI and SARI cases regularly, using the Integrated Health Information Platform (IHIP) portal.

Genome Sequencing: States were advised to send positive samples for genome sequencing to INSACOG laboratories to enable timely detection of new variants, considering the recent detection of the JN.1 variant in Kerala.

Community Awareness: States were encouraged to actively promote community awareness and seek continued public support in managing Covid-19, emphasizing adherence to respiratory hygiene.

The advisory comes in the wake of India detecting its first case of the JN.1 variant in Kerala. The 79-year-old patient with mild Influenza-like symptoms has fully recovered. Kerala Health Minister Veena George reassured the public, stating that the JN.1 variant had been detected months ago in Indian passengers screened at Singapore Airport. While causing a surge in infections worldwide, health authorities remain vigilant, especially given its spread to over 20 countries since its identification in Luxembourg.

The government's advisory underscores the critical need for proactive measures and collaboration between public and private health facilities to effectively manage the evolving situation.

[newsdaynight]

ओमीक्रोन XBB.1.16: बूस्‍टर डोज पर भी हावी हो रहा नया वेरिएंट तभी तो फिर फैलने लगा कोराना, जानें कितना खतरनाक

Delhi: नई दिल्‍ली: देश में तेजी से बढ़ रहे कोविड केसेज के पीछे ओमीक्रोन का नया सबवेरिएंट XBB.1.16 जिम्मेदार है। हालिया मामलों के जीनोम एनालिसिस से एक बात सामने आई है। जीनॉमिक्‍स कंसोर्टियम INSACOG के एक सदस्य ने हमारे सहयोगी द इकॉनमिक टाइम्स को बताया कि भारत में 60% केसेज में XBB.1.16 ��िल रहा है। उसके ऊपर 25-30% मामले ऐसे हैं जो इसी XBB वेरिएंट के सबलीनिएज हैं। मतलब ओमीक्रोन का XBB सबवेरिएंट देश के करीब 90% कोरोना मामलों के पीछे है। डेली पॉजिटिविटी रेट 2.87 प्रतिशत हो गया है। पिछले हफ्ते के मुकाबले पॉजिटिविटी रेट दोगुना हो गया है। XBB.1.16 को लेकर विश्‍व स्‍वास्‍थ्‍य संगठन (WHO) ने भी आगाह किया है। WHO के मुताबिक, XBB.1.16 सबवेरिएंट पर नजर रखने की जरूरत है। अभी तक यह सबवेरिएंट 22 देशों में मिला है। भारत में इसका पहला केस पिछले साल फरवरी में पुणे से मिला था। अब इसने कोरोना के बाकी सारे वेरिएंट्स को पीछे छोड़ दिया है। XBB.1.16 वेरिएंट क्‍यों इतना खतरनाक है, किसलिए इतनी तेजी से फैल रहा है, लक्षण और इलाज कैसे हो रहा है, जानिए हर बात। http://dlvr.it/SlvHc6

[bausabour]

Surge in Covid-19 cases in India linked to highly contagious XBB1.16 variant

Surge in Covid-19 infections in India linked to 349 cases of XBB1.16 variant India has seen a surge in daily Covid-19 infections, with 349 cases of the newly detected XBB1.16 variant, which may be responsible for the recent increase in cases. According to data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG), Maharashtra has the highest number of XBB1.16 variant cases with 105 cases,…

[worldspotlightnews]

India sees a jump in COVID XBB 1.16 cases, H3N2 scare looms high: Know the symptoms and how to prevent these viral attacks | The Times of India

As per the INSACOG, the forum that studies and monitors genome sequencing and virus variation of circulating strains of COVID-19 in India, a total of 76 samples of new COVID variant XBB 1.16 has been found in the country. As per the official data, the samples have been found in Karnataka, Maharashtra, Puducherry, Delhi, Telangana, Gujarat, Himachal Pradesh and Odisha. The highest number of XBB…

[newsbios]

ભારતમાં નવા કોવિડ વેરિઅન્ટ XBB1.16 ના 76 નમૂનાઓ મળ્યા: INSACOG ડેટા | ભારત સમાચાર

નવી દિલ્હી: કોવિડ-19ના XBB.1.16 વેરિઅન્ટના કુલ 76 નમૂનાઓ મળી આવ્યા છે જે દેશમાં તાજેતરના કેસો વધવા પાછળ હોઈ શકે છે, INSACOG ડેટા અનુસાર.આ પ્રકાર સમગ્ર કર્ણાટકમાં જોવા મળ્યો છે (30), મહારાષ્ટ્ર (29), પુડુચેરી (7) દિલ્હી (5), તેલંગાણા (2), ગુજરાત (1), હિમાચલ પ્રદેશ (1) અને ઓડિશા (1), ભારતીય SARS-CoV-2 જેનોમિક્સ કન્સોર્ટિયમ (INSACOG) ડેટા દર્શાવે છે.XBB 1.16 વેરિઅન્ટ સૌપ્રથમ જાન્યુઆરીમાં જોવા મળ્યો…

[newswireml]

76 samples of new Covid-19 variant XBB1.16 found in India: INSACOG data#samples #Covid19 #variant #XBB116 #India #INSACOG #data

A total of 76 samples of COVID-19’s XBB.1.16 variant have been found which might be behind the recent rise of cases in the country, according to INSACOG data. The variant has been found across Karnataka (30), Maharashtra (29), Puducherry (7) Delhi (5), Telangana (2), Gujarat (1), Himachal Pradesh (1) and Odisha (1), the Indian SARS-CoV-2 Genomics Consortium (INSACOG) data showed. The XBB 1.16…

[newstakatk]

Omicron's XBB Most Prevalent Sub-Lineage Circulating All Over India: INSACOG Bulletin

[unpluggedtv]

A fresh instance of the XBB 1.5 strain has apparently been found in Uttarakhand. Before three instances were found in Gujarat, one case each was found in Karnataka, Telangana, Chhattisgarh, and Rajasthan.

The XBB.1.5 strain is connected to the Omicron XBB variant, a recombinant of the Omicron BA.2.10.1 and BA.2.75 subvariants. Together, XBB and XBB.1.5 account for 44% of cases in the US.

The XBB 1.5 strain is responsible for the Covid-19 cases in the United States, but the INSACOG data has revealed that nine cases of the BF.7 strain, which is suspected to be responsible for the coronavirus outbreak in China, have been found.

Sub-variant BF of Omicron.

In seven cases—four in West Bengal, two in Gujarat, one in Haryana—there have been seven occurrences found.

Read More: https://unpluggedtv.in/india-reports-new-case-of-omicron-xbb-variant-total-8-cases/

Covid-19 Prevention Network Covid 19 Outbreaks - County Durham 𝗖 𝗢 𝗩 𝗜 𝗗 Covid Protect

[gujaratiqanswerdotin]

ભારતમાં કોરોનાવાયરસ: કોરોના વાયરસના XBB.1.5 વેરિઅન્ટની સંખ્યા વધીને 7 થઈ, જાણો કેટલા રાજ્યમાં

ભારતમાં કોરોનાવાયરસ: કોરોના વાયરસના XBB.1.5 વેરિઅન્ટની સંખ્યા વધીને 7 થઈ, જાણો કેટલા રાજ્યમાં

ભારતમાં કોરોનાવાયરસ: જ્યાં ચીનમાં કોરોનાનું સંક્રમણ સતત વધી રહ્યું છે, ત્યાં ભારતમાં કોરોના વાયરસના XBB.1.5 વેરિઅન્ટની સંખ્યા વધીને સાત થઈ ગઈ છે. ભારતીય SARS-COV-2 જેનોમિક્સ કન્સોર્ટિયમ (INSACOG)ના ડેટામાં આ માહિતી આપવામાં આવી છે. તમને જણાવી દઈએ કે અમેરિકામાં કોરોના વાયરસના સંક્રમણના નવા કેસ વધવા માટે આ વેરિઅન્ટ જવાબદાર હોવાનું કહેવાય છે. ક��ા રાજ્યમાં કેટલા કેસ INSACOG ડેટા અનુસાર, સાત કેસમાંથી…

[morningmantra]

COVID subvariant JN.1: In Kerala, the covid subvariant is JN.1

A subtype of Covid-19 called JN.1 has come to light in Kerala. This was revealed in the observations conducted by the Indian Sars-Cov-2 Genomics Consortium (INSACOG).

A subtype of Covid-19 called JN.1 has come to light in Kerala. This was revealed in the observations conducted by the Indian Sars-Cov-2 Genomics Consortium (INSACOG). A new sub-variant found in a women Delhi: A subtype of Covid-19 called JN.1 (COVID subvariant JN.1) has come to light in Kerala. This was revealed in the observations conducted by the Indian Sars-Cov-2 Genomics Consortium…

[rnewspost]

2 More Cases Of Covid Variant Behind Rise In US Numbers Found In India

2 More Cases Of Covid Variant Behind Rise In US Numbers Found In India

New cases of the variant were found in Chhattisgarh and Telangana New Delhi: The number of COVID-19’s XBB.1.5 variant, responsible for the rise in cases in the US, rose to seven in India as new cases of the variant were found in Chhattisgarh and Telangana, according to INSACOG figures on Thursday. Of the seven cases, three were found in Gujarat and one each in Karnataka, Telangana, Chhattisgarh…